Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Palmitoyl tetrapeptide-7 is a synthetic lipopeptide composed of the amino acid sequence glycine-glutamine-proline-arginine (GQPR) attached to a palmitic acid moiety, which enhances its lipid solubility and skin penetration. It is primarily used in cosmetic and dermatological products for its anti-inflammatory and anti-aging properties. The mechanism of action involves reducing the production of interleukin 6 (IL‑6), a pro-inflammatory cytokine that accelerates collagen breakdown and skin aging. By decreasing IL‑6 levels, it helps slow down collagen degradation, reduce inflammation, promote synthesis of type I collagen, fibronectin, and hyaluronic acid, leading to improved skin elasticity and reduced appearance of wrinkles. It is often used in combination with other peptides such as palmitoyl tripeptide‑1 in formulations like Matrixyl 3000[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on palmitoyl tetrapeptide-7.